מתוך medicontext.co.il
WASHINGTON (Reuters Health) – The US Food and Drug Administration (FDA) issued on Wednesday a final rule banning over-the-counter combination oral drug products that pair a bronchodilator with an analgesic, analgesic-antipyretic, anticholinergic, antihistamine, antitussive or stimulant active ingredient.
The agency said that it knows of no currently-marketed OTC drugs that meet that description.
Oral bronchodilator active ingredients include ephedrine and related substances. The FDA has in the past voiced strong concerns about weight-loss dietary supplements that combine ephedrine/ephedra with stimulants like caffeine. The new rule–while applying only to cough, cold and allergy drugs–serves to fortify the agency's position that such ingredient combinations may be unsafe.
The final rule will take effect 30 days after its scheduled publication in Thursday's Federal Register. It is part of the FDA's ongoing review of OTC products.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!